Notalgia paresthetica (NP) is a nerve condition that causes itchiness and sometimes pain on the back. It tends to affect a specific area — usually under a shoulder blade and often on the left side.

Notalgia paresthetica isn't linked with and doesn't increase your risk for any cancer. When itchy skin is a warning sign of cancer , it's typically a body-wide itch or in an area other than your back.

Notalgia Paresthetica (NP) is a sensory neuropathy marked by localised itching and pain, which may or may not be accompanied by a distinct hyperpigmented patch on the upper back.

The phase II study included 125 adults with notalgia paresthetica enrolled at 28 sites in North America. They were randomized 1:1 to difelikefalin (2 mg) or matching placebo twice daily for 8 weeks.

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026 Jan. 22, 2024 7:00 AM ET Tvardi Therapeutics, Inc. (TVRD) ...

Cara Therapeutics Inc (NASDAQ: CARA) announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia paresthetica (NP). Notalgia ...

STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia ...

--Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from ...

STAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...

--Cara Therapeutics, Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/ 3 clinical program in notalgia paresthetica and significantly reduce its operating expenses.

– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued ...